8-K: Dermata Therapeutics Granted Extension to Regain Nasdaq Listing Compliance Amidst Delisting Threat

Dermata Therapeutics, Inc. has received an exception from Nasdaq until August 14, 2025, to regain compliance with the minimum bid price requirement, following a prior delisting notice.

Summary

• Dermata Therapeutics, Inc. (DRMA) was notified on May 14, 2025, by Nasdaq's Listing Qualifications Department that it was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing.
• The company's securities were subject to delisting from the Nasdaq Capital Market and would have been suspended on May 23, 2025, due to a reverse stock split implemented within the prior one-year period.
• Dermata Therapeutics timely requested a hearing before the Nasdaq Panel, which stayed any further suspension or delisting action.
• On July 2, 2025, the Nasdaq Panel granted the company an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement.
• The company is required to promptly notify the Panel of any significant events that may question its ability to satisfy the exception terms.
• Dermata Therapeutics is actively pursuing measures to regain compliance, including seeking shareholder approval for a reverse stock split at its annual stockholders meeting on July 15, 2025, and implementing it if approved.

Sentiment

Score: 4

Explanation: The situation is negative due to ongoing non-compliance and delisting risk, but the temporary reprieve from Nasdaq provides a crucial window for the company to address the issue, preventing immediate adverse action.

Positives

• The Nasdaq Panel granted Dermata Therapeutics an exception until August 14, 2025, providing additional time to regain compliance with the minimum bid price requirement.
• The request for a hearing successfully stayed the immediate suspension and delisting action by Nasdaq.

Negatives

• Dermata Therapeutics is currently not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company's securities were subject to delisting and suspension due to non-compliance and a prior reverse stock split within the last year.
• There is no assurance that the company will be able to regain compliance and maintain its listing on the Nasdaq Capital Market.

Risks

• Failure to regain compliance with the Nasdaq Minimum Bid Price Requirement by August 14, 2025.
• Failure to satisfy other Nasdaq requirements for continued listing.
• Potential delisting of the company's securities from the Nasdaq Capital Market.
• Inability to gain shareholder approval for a reverse stock split.
• Inability to timely implement a reverse stock split if approved.

Future Outlook

Dermata Therapeutics intends to regain compliance with the Nasdaq Minimum Bid Price Rule by seeking shareholder approval for a reverse stock split at its annual meeting on July 15, 2025, and implementing it if approved. However, there is no assurance that the company will be able to regain compliance and maintain its Nasdaq listing.

Management Comments

• The company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement.
• The company will seek shareholder approval for a reverse stock split at its annual stockholders meeting on July 15, 2025, and if approved, will implement a reverse stock split.

Industry Context

Maintaining listing compliance, particularly minimum bid price requirements, is a common challenge for smaller biotechnology and pharmaceutical companies, especially those in clinical development stages without significant revenue streams. Reverse stock splits are a frequent strategy employed by such companies to meet these requirements and avoid delisting, which can severely impact liquidity and investor confidence.

Corporate Governance

Legal Proceedings

• The company engaged in a hearing process with the Nasdaq Panel regarding its non-compliance with listing rules, which resulted in an exception being granted.

Stakeholder Impact

• Shareholders face uncertainty regarding the company's continued listing on Nasdaq, which could impact liquidity and share value.
• Shareholders will vote on a reverse stock split, which will alter their ownership structure (fewer shares at a higher price per share).

Next Steps

• Provide prompt notification to the Nasdaq Panel of any significant events that may call into question the company's ability to satisfy the terms of the exception.
• Hold the annual stockholders meeting on July 15, 2025, to seek shareholder approval for a reverse stock split.
• If approved by shareholders, implement a reverse stock split.
• Demonstrate compliance with the Nasdaq Minimum Bid Price Requirement by August 14, 2025.

Key Dates

Recommendation

Keywords

Nasdaq, listing compliance, minimum bid price, reverse stock split, delisting, Dermata Therapeutics, DRMA, Form 8-K, stock market, corporate governance